Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in intron 26 of the CEP290 gene ("LCA10-IVS26").
This is an open-label, single ascending dose study of EDIT-101 in adult and pediatric (ie, ages 3 to 17) participants with LCA10-IVS26. Up to 34 participants will be enrolled in up to 5 cohorts to evaluate up to 3 dose levels of EDIT-101 in this study. EDIT-101 is a novel gene editing product designed to eliminate the mutation on the CEP290 gene that results in the retinal degeneration that defines LCA10-IVS26.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adults Low Dose | Experimental | Single dose of EDIT-101 administered by subretinal injection surgery |
|
| Adults Middle Dose | Experimental | Single dose of EDIT-101 administered by subretinal injection surgery |
|
| Adults High Dose | Experimental | Single dose of EDIT-101 administered by subretinal injection surgery |
|
| Pediatric Middle Dose | Experimental | Single dose of EDIT-101 administered by subretinal injection surgery |
|
| Pediatric High Dose | Experimental | Single dose of EDIT-101 administered by subretinal injection surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EDIT-101 | Drug | Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of Adverse Events related to EDIT-101 | 1 year | |
| Number of participants experiencing procedural related adverse events | 1 year | |
| Incidence of dose limiting toxicities | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum tolerated dose as determined by occurrence of dose limiting toxicities | 1 year | |
| Change from baseline in Mobility course score | Testing the subjects visual function by having the subject walk through obstacle courses. Courses will have different levels of difficulty depending on the light levels of the room and the contrast of the objects in the room. |
Not provided
Inclusion Criteria:
Male or female
At least 3 years of age at screening with CEP290-related retinal degeneration caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in IVS26 of the CEP290 gene.
Visual Acuity:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bascom Palmer Eye Institute | Miami | Florida | 33136 | United States | ||
| Massachusetts Eye and Ear Infirmary |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38709228 | Derived | Pierce EA, Aleman TS, Jayasundera KT, Ashimatey BS, Kim K, Rashid A, Jaskolka MC, Myers RL, Lam BL, Bailey ST, Comander JI, Lauer AK, Maguire AM, Pennesi ME. Gene Editing for CEP290-Associated Retinal Degeneration. N Engl J Med. 2024 Jun 6;390(21):1972-1984. doi: 10.1056/NEJMoa2309915. Epub 2024 May 6. | |
| 34629400 | Derived |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| Change from baseline in LogMAR measurement of BCVA | The test will evaluate visual acuity in ranges from light perception to normal vision. | 1 year |
| Change from baseline in pupillary response | Measuring the change in pupil diameter in response to a light stimulus. | 1 year |
| Change from baseline in dark adapted visual sensitivity using Full field light sensitivity threshold (FST) | Flashes of light of varying luminance are presented to the eye and the subject reports is the flash was seen. | 1 year |
| Change from baseline in macula thickness | 1 year |
| Change from baseline in contrast sensitivity | The Lea symbols chart will be used for subjects under age 6 and the Pelli-Robson chart for all other subjects. The images or letters on the charts are in decreasing contrast. | 1 year |
| Change from baseline in macular sensitivity as measured by microperimetry | Visual field test measuring the amount of light perceived in specific parts of the macula. | 1 year |
| Change from baseline in color vision score using the Farnsworth 15 score | The Farnsworth D15 tests for congenital and acquired color vision defects. Fifteen color discs will be arranged by the subject. Scoring is accomplished by recording the sequence selected by the patient on a copy of the score sheet. A patient with a color vision deficiency will arrange the color discs in a different order than a person with normal color vision. | 1 year |
| Change from baseline in QOL score for Age <8 years using the Children's Visual Function Questionnaire | 1 year |
| Change from baseline in QOL score for Age 8 to <18 years using the Impact of Vision Impairment for Children | 1 year |
| Change from baseline in QOL score for Age >18 years if BCVA is worse than 1.0 logMAR in both eyes using the Impact of Vision Impairment for Very Low Vision | 1 year |
| Change from baseline in QOL score for Age >18 years if BCVA is 1.0 logMAR or better in both eyes using the Impact of Vision Impairment | 1 year |
| Change from baseline in visual field using kinetic perimetry | Kinetic perimetry looks as the visual field to identify regions of normal and abnormal sensitivity to light | 1 year |
| Change from baseline in Patient Global Impressions of Change score | This QOL has 5 non-numeric choices for the subject to select how they believe their condition has changed. | 1 year |
| Change from baseline in gaze tracking | Video clips of the eyes are used to measure eye position and stability over time. | 1 year |
| Boston |
| Massachusetts |
| 02114 |
| United States |
| W.K. Kellogg Eye Center - University of Michigan | Ann Arbor | Michigan | 48105 | United States |
| Casey Eye Institute - OSHU | Portland | Oregon | 97239 | United States |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| Harvey JP, Sladen PE, Yu-Wai-Man P, Cheetham ME. Induced Pluripotent Stem Cells for Inherited Optic Neuropathies-Disease Modeling and Therapeutic Development. J Neuroophthalmol. 2022 Mar 1;42(1):35-44. doi: 10.1097/WNO.0000000000001375. Epub 2021 Sep 30. |
| 33497524 | Derived | Zhang X, Zhang D, Thompson JA, Chen SC, Huang Z, Jennings L, McLaren TL, Lamey TM, De Roach JN, Chen FK, McLenachan S. Gene correction of the CLN3 c.175G>A variant in patient-derived induced pluripotent stem cells prevents pathological changes in retinal organoids. Mol Genet Genomic Med. 2021 Mar;9(3):e1601. doi: 10.1002/mgg3.1601. Epub 2021 Jan 26. |
| ID | Term |
|---|---|
| C565720 | Leber Congenital Amaurosis 10 |
| D015785 | Eye Diseases, Hereditary |
| D012164 | Retinal Diseases |
| D012162 | Retinal Degeneration |
| D014786 | Vision Disorders |
| D005124 | Eye Abnormalities |
| C567003 | Meckel Syndrome, Type 4 |
| D057130 | Leber Congenital Amaurosis |
| D030342 | Genetic Diseases, Inborn |
| D000013 | Congenital Abnormalities |
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D012678 | Sensation Disorders |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided